JP2022549222A - アンドロゲン受容体分解活性を有する新規尿素およびその使用 - Google Patents

アンドロゲン受容体分解活性を有する新規尿素およびその使用 Download PDF

Info

Publication number
JP2022549222A
JP2022549222A JP2022517875A JP2022517875A JP2022549222A JP 2022549222 A JP2022549222 A JP 2022549222A JP 2022517875 A JP2022517875 A JP 2022517875A JP 2022517875 A JP2022517875 A JP 2022517875A JP 2022549222 A JP2022549222 A JP 2022549222A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
carboxamide
dimethylpiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549222A5 (https=
Inventor
ジエ ファン，
イミン チアン，
ウェイ ヘ，
ケ リウ，
Original Assignee
アキュター バイオテクノロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキュター バイオテクノロジー インコーポレイテッド filed Critical アキュター バイオテクノロジー インコーポレイテッド
Publication of JP2022549222A publication Critical patent/JP2022549222A/ja
Publication of JP2022549222A5 publication Critical patent/JP2022549222A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022517875A 2019-09-23 2020-09-22 アンドロゲン受容体分解活性を有する新規尿素およびその使用 Pending JP2022549222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903997P 2019-09-23 2019-09-23
US62/903,997 2019-09-23
PCT/US2020/051997 WO2021061642A1 (en) 2019-09-23 2020-09-22 Novel ureas having androgen receptor degradation activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2022549222A true JP2022549222A (ja) 2022-11-24
JP2022549222A5 JP2022549222A5 (https=) 2023-09-28

Family

ID=74879893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517875A Pending JP2022549222A (ja) 2019-09-23 2020-09-22 アンドロゲン受容体分解活性を有する新規尿素およびその使用

Country Status (5)

Country Link
US (3) US11420956B2 (https=)
EP (1) EP4034114A4 (https=)
JP (1) JP2022549222A (https=)
CN (1) CN114761003B (https=)
WO (1) WO2021061642A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535054A (ja) * 2020-07-21 2023-08-15 ユービックス セラピューティクス インコーポレイテッド アンドロゲン受容体分解用化合物及びその医薬用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
EP3917916A4 (en) 2019-01-30 2022-12-14 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
WO2023039604A1 (en) * 2021-09-13 2023-03-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
KR20230112501A (ko) 2022-01-20 2023-07-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해활성을 갖는 화합물 및 이들의 의약 용도
US20240190842A1 (en) * 2022-11-09 2024-06-13 Accutar Biotechnology Inc. Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
JP2001503384A (ja) * 1996-07-24 2001-03-13 セルジーン コーポレイション 置換２―（２，６―ジオキソピペリジン―３―イル）フタルイミド類及び―１―オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
WO2004007471A1 (ja) * 2002-07-12 2004-01-22 Yamanouchi Pharmaceutical Co., Ltd. Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US8158653B2 (en) * 1999-05-07 2012-04-17 Celgene Corporation Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline
WO2012053630A1 (ja) * 2010-10-22 2012-04-26 アステラス製薬株式会社 変異アンドロゲン受容体拮抗薬
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
US20180179183A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011011A1 (en) * 2003-07-21 2005-02-03 Unaxis Usa Inc. Etching method for making chalcogenide memory elements
SMT201900735T1 (it) * 2012-07-27 2020-03-13 Aragon Pharmaceuticals Inc Metodi e composizioni per determinare la resistenza a una terapia verso recettore degli androgeni
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503384A (ja) * 1996-07-24 2001-03-13 セルジーン コーポレイション 置換２―（２，６―ジオキソピペリジン―３―イル）フタルイミド類及び―１―オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US8158653B2 (en) * 1999-05-07 2012-04-17 Celgene Corporation Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline
WO2004007471A1 (ja) * 2002-07-12 2004-01-22 Yamanouchi Pharmaceutical Co., Ltd. Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2012053630A1 (ja) * 2010-10-22 2012-04-26 アステラス製薬株式会社 変異アンドロゲン受容体拮抗薬
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180179183A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
WO2018119448A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535054A (ja) * 2020-07-21 2023-08-15 ユービックス セラピューティクス インコーポレイテッド アンドロゲン受容体分解用化合物及びその医薬用途
JP7557230B2 (ja) 2020-07-21 2024-09-27 ユービックス セラピューティクス インコーポレイテッド アンドロゲン受容体分解用化合物及びその医薬用途

Also Published As

Publication number Publication date
US20210300901A1 (en) 2021-09-30
US11420956B2 (en) 2022-08-23
WO2021061642A1 (en) 2021-04-01
EP4034114A4 (en) 2023-07-26
US20230150973A1 (en) 2023-05-18
CN114761003B (zh) 2023-12-29
US11220490B2 (en) 2022-01-11
CN114761003A (zh) 2022-07-15
EP4034114A1 (en) 2022-08-03
US20210087170A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP7307796B2 (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
JP2022549222A (ja) アンドロゲン受容体分解活性を有する新規尿素およびその使用
JP7662639B2 (ja) エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用
EP3675839B1 (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
US11535606B2 (en) Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
JP2024505558A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）分解剤としての置換ピロロピリミジンおよびピラゾロピリミジン
US20240190842A1 (en) Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof
CA3054459A1 (en) Azetidine derivative
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
HK40041475A (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
HK40041475B (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250221